Zacks Research Predicts Stronger Earnings for Teladoc Health

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Investment analysts at Zacks Research boosted their Q2 2025 earnings estimates for Teladoc Health in a research note issued on Wednesday, May 14th. Zacks Research analyst R. Department now anticipates that the health services provider will post earnings per share of ($0.26) for the quarter, up from their prior estimate of ($0.28). The consensus estimate for Teladoc Health's current full-year earnings is ($1.16) per share. Zacks Research also issued estimates for Teladoc Health's Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.29) EPS and FY2027 earnings at ($0.85) EPS.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The company had revenue of $640.49 million during the quarter, compared to the consensus estimate of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler decreased their target price on shares of Teladoc Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Jefferies Financial Group reduced their target price on Teladoc Health from $10.00 to $8.00 and set a "hold" rating for the company in a research note on Monday, April 21st. Wells Fargo & Company reduced their target price on Teladoc Health from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a research report on Thursday, May 1st. Finally, Stifel Nicolaus reduced their target price on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Thursday, May 1st. Twelve investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.71.

Teladoc Health Stock Down 1.2%

TDOC stock traded down $0.09 during mid-day trading on Monday, reaching $6.82. The company had a trading volume of 4,118,390 shares, compared to its average volume of 6,241,311. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The stock has a 50 day simple moving average of $7.42 and a two-hundred day simple moving average of $9.29. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.18 and a beta of 1.82. Teladoc Health has a 52 week low of $6.35 and a 52 week high of $15.21.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. increased its stake in shares of Teladoc Health by 21.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 700,166 shares of the health services provider's stock valued at $6,365,000 after acquiring an additional 125,111 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Teladoc Health by 20,936.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 426,206 shares of the health services provider's stock worth $3,874,000 after purchasing an additional 424,180 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Teladoc Health by 18.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,443,713 shares of the health services provider's stock worth $22,213,000 after buying an additional 384,528 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Teladoc Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 3,947,831 shares of the health services provider's stock worth $35,894,000 after acquiring an additional 22,664 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Teladoc Health by 35.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 113,563 shares of the health services provider's stock valued at $1,032,000 after acquiring an additional 29,903 shares in the last quarter. Institutional investors own 76.82% of the company's stock.

Insider Activity at Teladoc Health

In other news, insider Adam C. Vandervoort sold 11,011 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $8.42, for a total transaction of $92,712.62. Following the completion of the transaction, the insider now directly owns 64,308 shares in the company, valued at $541,473.36. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.58% of the stock is owned by company insiders.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.